CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Samsung Bioepis Co., Ltd. vs. REGENERON PHARMACEUTICALS, INC.

📡 5G SEP • ETSI Declared

Explore the PTAB proceeding IPR2023-01312 filed by Samsung Bioepis Co., Ltd. on 2023-08-18. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2023-01312

Filing Date

2023-08-18

Accorded Filing Date

2023-08-18

Institution Decision Date

2023-12-08

Last Modified Date

2024-05-24

Proceeding Type

IPR

Termination Date

2024-02-21

Trial Status

Terminated-Adverse Judgment

Parties & Counsel

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 16159269
Respondent Patent Number 10464992
Legal Expiration Date
2038-10-12 Active (11.9 yrs remaining)
Injunction Viability (35 U.S.C. § 283) Active Threat
Respondent Inventor Eric FURFINE et al
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

2 Total

Proceeding Status

Terminated-Adverse Judgment

Board Decisions & Rulings (2)

Request For Adverse Judgment After Institution 2024-02-21
Adverse Judgment After Institution of Trial 37 C.F.R. § 42.73(b)
35 USC 314, 37 CFR 42.73
Institution Granted(Joined) 2023-12-08
Institution Decision: DECISION Granting Institution of Inter Partes Review 35 U.S.C. § 314 Granting Motion for Joinder 35 U.S.C. § 315(c); 37 C.F.R. § 42.122
37 CFR 42.122, 35 USC 314, 37 CFR 42.72, 35 USC 315

Address and Attorney/Agent Information

23 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name A&P - Regeneron (Prosecution)
Customer Number 191459
Address 601 Massachusetts Ave., NW, Washington, DC, 20001-3743, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
41408 David Marsh +1 202-942-5068
48001 Thomas Triolo +1 914-847-1612
48921 Stephen Gaudet +1 914-847-7376
50370 Neil Miyamoto +1 914-847-7175
50437 Frank Cottingham +1 914-593-1116
58583 Brian Cocca +1 914-847-1421
58714 Ilona Gont +1 914-847-1304
59668 Brandon Schurter +1 914-847-7000

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 16 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 2 proceedings
🏛️
USPTO PTAB Trials 6 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (16): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (8 found):
PTAB: 6 U.S. Courts: 2
USPTO PTAB Trial 2025-07-14
IPR2025-01268

Fresenius Kabi SwissBioSim GmbH et al. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11084865)
Status: Discretionary Denial
USPTO PTAB Trial 2025-01-15
IPR2025-00456

Celltrion, Inc. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11084865)
Status: Discretionary Denial
USPTO PTAB Trial 2024-12-02
IPR2025-00233

Formycon AG v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11084865)
Status: Institution Denied
USPTO PTAB Trial 2024-11-20
IPR2025-00176

Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.

U.S. Continuation Sibling (11084865)
Status: Institution Denied
USPTO PTAB Trial 2023-01-17
IPR2023-00462

Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Terminated-Adverse Judgment
USPTO PTAB Trial 2021-01-07
IPR2021-00402

Chengdu Kanghong Biotechnology Co., Ltd. et al. v. Regeneron Pharmaceuticals, Inc.

Asserted Patent
Status: Terminated
U.S. District Court 2024-05-17
1:24-cv-00053

Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc.

U.S. Family Sibling (["US 11084865", "US 11,084,865", "US11,084,865", "11084865", "US11084865", "11,084,865"])
Status: WVND
U.S. District Court 2023-11-21
1:23-cv-00094

Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD.

U.S. Family Sibling (["US 11084865", "US 11,084,865", "US11,084,865", "11084865", "US11084865", "11,084,865"])
Status: WVND
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP • ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 5G NR Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Samsung

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

✓ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
✓ Right to demand global FRAND portfolio determination.
✓ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

54
8

Adverse Judgment After Institution of Trial 37 C.F.R. § 42.73(b) ADVRSJUDG

2024-02-21 FILING PARTY: BOARD
3001

Exhibit 3001 Exhibit

2024-02-21 FILING PARTY: BOARD
7

Institution Decision: DECISION Granting Institution of Inter Partes Review 35 U.S.C. § 314 Granting Motion for Joinder 35 U.S.C. § 315(c); 37 C.F.R. § 42.122 OTHER

2023-12-08 FILING PARTY: BOARD
4

Notice: Notice filing date accorded NOTICE

2023-08-30 FILING PARTY: BOARD
1014

Parkins 2000 Exhibit

2023-08-18 FILING PARTY: PETITIONER

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc